These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 38131253)

  • 1. Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.
    Bertero E; Chiti C; Schiavo MA; Tini G; Costa P; Todiere G; Mabritto B; Dei LL; Giannattasio A; Mariani D; Lofiego C; Santolamazza C; Monda E; Quarta G; Barbisan D; Mandoli GE; Mapelli M; Sguazzotti M; Negri F; De Vecchi S; Ciabatti M; Tomasoni D; Mazzanti A; Marzo F; de Gregorio C; Raineri C; Vianello PF; Marchi A; Biagioni G; Insinna E; Parisi V; Ditaranto R; Barison A; Giammarresi A; De Ferrari GM; Priori S; Metra M; Pieroni M; Patti G; Imazio M; Perugini E; Agostoni P; Cameli M; Merlo M; Sinagra G; Senni M; Limongelli G; Ammirati E; Vagnarelli F; Crotti L; Badano L; Calore C; Gabrielli D; Re F; Musumeci G; Emdin M; Barbato E; Musumeci B; Autore C; Biagini E; Porto I; Olivotto I; Canepa M
    Eur J Heart Fail; 2024 Jan; 26(1):59-64. PubMed ID: 38131253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
    Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
    JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
    Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
    J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.
    Masri A; Lester SJ; Stendahl JC; Hegde SM; Sehnert AJ; Balaratnam G; Shah A; Fox S; Wang A
    J Am Heart Assoc; 2024 Apr; 13(8):e030607. PubMed ID: 38591260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
    Rader F; Oręziak A; Choudhury L; Saberi S; Fermin D; Wheeler MT; Abraham TP; Garcia-Pavia P; Zwas DR; Masri A; Owens A; Hegde SM; Seidler T; Fox S; Balaratnam G; Sehnert AJ; Olivotto I
    JACC Heart Fail; 2024 Jan; 12(1):164-177. PubMed ID: 38176782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
    Cresci S; Bach RG; Saberi S; Owens AT; Spertus JA; Hegde SM; Lakdawala NK; Nilles EK; Wojdyla DM; Sehnert AJ; Wang A
    Circulation; 2024 Feb; 149(7):498-509. PubMed ID: 37961906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eighteen-Month Real-World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population.
    Ramonfaur D; Gasperetti A; Blake VE; Rivers B; Kassamali AA; Kasper EK; Barouch LA; Wu KC; Madrazo JA; Carrick RT
    J Am Heart Assoc; 2024 Aug; 13(15):e034069. PubMed ID: 39082420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy.
    Burstein Waldman C; Owens A
    Future Cardiol; 2021 Oct; 17(7):1269-1275. PubMed ID: 34018809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
    Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O
    Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
    Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
    Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy.
    Pysz P; Rajtar-Salwa R; Smolka G; Olivotto I; Wojakowski W; Petkow-Dimitrow P
    Kardiol Pol; 2021; 79(9):949-954. PubMed ID: 34268723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.
    Desai MY; Okushi Y; Gaballa A; Wang Q; Geske JB; Owens AT; Saberi S; Wang A; Cremer PC; Sherrid M; Lakdawala NK; Tower-Rader A; Fermin D; Naidu SS; Lampl KL; Sehnert AJ; Nissen SE; Popovic ZB;
    Circ Cardiovasc Imaging; 2024 Sep; 17(9):e017185. PubMed ID: 39221824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
    Desai MY; Owens A; Wolski K; Geske JB; Saberi S; Wang A; Sherrid M; Cremer PC; Lakdawala NK; Tower-Rader A; Fermin D; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Mudarris L; Gong Z; Lampl K; Sehnert AJ; Nissen SE
    JAMA Cardiol; 2023 Oct; 8(10):968-977. PubMed ID: 37639243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
    Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
    Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
    Chase Cole J; Benvie SF; DeLosSantos M
    Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Spertus JA; Fine JT; Elliott P; Ho CY; Olivotto I; Saberi S; Li W; Dolan C; Reaney M; Sehnert AJ; Jacoby D
    Lancet; 2021 Jun; 397(10293):2467-2475. PubMed ID: 34004177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
    Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE
    Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mavacamten (Camzyos ®) : first myosin modulator for obstructive hypertrophic cardiomyopathy treatment].
    Lancellotti P; de Marneffe N; Scheen A
    Rev Med Liege; 2024 Feb; 79(2):120-128. PubMed ID: 38356430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.